| [1] |
邵志敏,沈镇宙,徐兵河.乳腺肿瘤学[M].上海:复旦大学出版社,2013:404-407.
|
| [2] |
Cox CE, Salud CJ, Harrinton MA. The role of selective sentinel lymph node dissection in breast cancer [J]. Surg Clin North Am, 2000,80(6):1759-1777.
|
| [3] |
Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial[J]. J Natl Cancer Inst,2006,98 (9):599-609.
|
| [4] |
Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer[J].Breast Cancer Res Treat,2006,95(3):279-293.
|
| [5] |
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial [J]. Lancet Oncol,2010,11(10):927-933.
|
| [6] |
Hunt KK, Ballman KV, McCall LM, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection:results of the ACOSOG Z0010 reial[J]. Ann Surg, 2012, 256 (3):428-436.
|
| [7] |
Veronesi U,Paganelli G,Viale G,et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer[J].N Engl J Med,2003,349(6):546-553.
|
| [8] |
Edge S, Byrd DR, Compton CC, et al. AJCC cancer staging handbook[M].7th ed. Chicago: Springer,2010:347-376.
|
| [9] |
Patani N, Mokbel K. The clinical significance of sentinel lymph node micrometastasis in breast cancer[J]. Breast Cancer Res Treat, 2009,114 (3):393-402.
|
| [10] |
Chen SL, Hochne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis[J]. Ann Surg Oncol,2007,14(12):3378-3384.
|
| [11] |
Salhab M, Patani N, Mokbel K. Sentinel lymph node micrometastasis in human breast cancer: an update[J]. Surg Oncol, 2011, 20 (4):e195-206.
|
| [12] |
Houssami N,Morrow M. Margins in breast conservation: a clinician's perspective and what the literature tells us [J]. J Surg Oncol, 2014,110(1):2-7.
|
| [13] |
邵志敏,李俊杰. 2015 年St.Gallen 国际乳腺癌研讨会乳腺癌新的诊疗理念[J/CD].中华乳腺病杂志:电子版,2015,9(2):73-77.
|
| [14] |
Yi M,Giordano SH,Meric-BernstamF,et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients:experience from the SEER database [J]. Ann Surg Oncol,2010,17 suppl 3:343-351.
|
| [15] |
de Boer M,van Deurzen CH,van Dijck JA,et,al. Micrometastases or isolated tumor cells and the outcome of breast cancer [J]. N Engl J Med,2009,361(7):653-663.
|
| [16] |
Massimino KP, Hessman CJ, Ellis MC, et al. Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest[J]. Ann J Surg,2012,203(5):618-622.
|
| [17] |
Giuliano AE, McCall L,Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial[J]. Ann Surg,2010,252(3):425-432.
|
| [18] |
Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011 [J]. J Clin Oncol,2007,25(24):3657-3663.
|
| [19] |
Harlow SP, Krag DN, Julian TB, et al. Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project(NSABP) B-32 trial: a randomized phase Ⅲclinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer[J]. Ann Surg,2005,241 (1):48-54.
|
| [20] |
Ashikaga T,Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection[J]. J Surg Oncol,2010,102(2):111-118.
|
| [21] |
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases(IBCSG 23-01): a phase 3 randomized controlled trial[J]. Lancet Oncol,2013,14(4):297-305.
|
| [22] |
范铁,范照青,英旻,等.前哨淋巴结活检替代腋窝淋巴结清扫安全性单中心资料分析[EB/OL].[2015-03-25]. http:/ /d.wanfangdata.com.cn/Conference/7757188.
|
| [23] |
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer(EORTC 10981-22023 AMAROS): a randomised, multicentre, openlabel, phase 3 non-inferiority trial [J]. Lancet Oncol,2014,15(12):1303-1310.
|
| [24] |
王永胜.乳腺癌前哨淋巴结活检共识与展望[J]. 中国普外基础与临床杂志,2009,16(7):505-509.
|
| [25] |
Caudle AS, Hunt KK, Kuerer HM, et al. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial [J]. Ann Surg Oncol,2011,18(9):2407-2412.
|
| [26] |
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy:updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J]. J Clin Oncol,2008,26 (5):778-785.
|
| [27] |
Kuehn T,Bauerfeind I, Fehm T, et al. Sentinel lymph-node biopsy in patients with breast cancer before and after neoadjuvant hemotherapy(SENTINA): a prospective, multicenter cohort study[J]. Lancet Oncol,2013,14(7):609-618.
|
| [28] |
Boughey JC, Suman VJ,Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J].JAMA,2013,310(14):1455-1461.
|
| [29] |
Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance) [J].Ann Surg,2015,261(3):547-552.
|
| [30] |
Boileau JF, Poirier B, Baski M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer:the SN FNAC study [J]. J Clin Oncol,2015,33(3):258-264.
|
| [31] |
左文述,郑美珠.乳腺癌新辅助化疗对局部区域外科治疗策略的影响[J].中国肿瘤外科杂志:2015,7(3):137-140.
|
| [32] |
Mieog JS, van der Hage JA, var de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer [J]. Br J Surg,2007,94(10):1189-1200.
|
| [33] |
Gradishar WJ, Anderson BO, Balassanian R,et al. NCCN Clinical practice guidelines in oncology (NCCN Guidelines®): breast cancer,version 2015[EB/OL].[2015-03-25]. https:/ /www.nccn.org/store/login/login.aspx? ReturnURL=http:/ /www. nccn. org/professionals/physician_gls/pdf/breast.pdf.
|